Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) EBT (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of EBT readings, the most recent being $4.7 million for Q4 2025.

  • On a quarterly basis, EBT rose 15660.0% to $4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$200.2 million, a 118.01% decrease, with the full-year FY2025 number at -$200.3 million, down 117.99% from a year prior.
  • EBT hit $4.7 million in Q4 2025 for Tandem Diabetes Care, up from -$25.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $11.1 million in Q4 2021 to a low of -$123.6 million in Q1 2023.
  • Median EBT over the past 5 years was -$23.9 million (2024), compared with a mean of -$29.5 million.
  • Biggest five-year swings in EBT: tumbled 908.82% in 2022 and later soared 15660.0% in 2025.
  • Tandem Diabetes Care's EBT stood at $11.1 million in 2021, then crashed by 245.5% to -$16.2 million in 2022, then crashed by 93.85% to -$31.3 million in 2023, then soared by 100.1% to $30000.0 in 2024, then soared by 15660.0% to $4.7 million in 2025.
  • The last three reported values for EBT were $4.7 million (Q4 2025), -$25.1 million (Q3 2025), and -$57.7 million (Q2 2025) per Business Quant data.